[Rapid viral response during treatment of chronic hepatitis B with pegylated interferon alfa-2a in children--preliminary report].
The aim of the study was to assess the viral response after 4 weeks of treatment with pegylated interferon alfa-2a chronic hepatitis B. Investigations were performed in 13 children in the age 11-17 years, with CHB, treated with PegIFN alfa-2a in the dose 100mcg/m2/week. After 4 weeks treatment statistically significant decrease of HBV viral load was observed. HBV DNA dissapearance was observed in 6/13 children with lower baseline ALT activity and lower HBV viral load before treatment. HBV DNA dissapearance was revealed in naïve children with anti-HBe serum presence. During treatment no adverse events following dosis modifications were observed. Our preliminary observations of early HBV viral load supression seem to reveal that peginterferon alfa-2a may be benefit therapeutic option for children with CHB.
Pawłowska
Małgorzata
M
Katedra i Klinika Chorób Zakaźnych i Hepatologii CM UMK. mpawlowska@cm.umk.pl
Halota
Waldemar
W
D000293:Adolescent; D000914:Antibodies, Viral; D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002648:Child; D004279:DNA, Viral / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006515:Hepatitis B virus / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011044:Poland; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D019562:Viral Load
D000914:Antibodies, Viral; D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a